InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.440 0.09 (25.71%)+
Announcement
Release
10 Jun 2026 8:53AM
Price at Release
$0.350
Full Release
download
Summary
Island Pharmaceuticals Limited announced an expansion of its Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) to support a dose optimisation study of Galidesivir for the treatment of Marburg Virus Disease. This study aims to determine the minimally effective dose against the Marburg Angola strain, with dosing to start 24 or 48 hours post-exposure and continuing for 14 days. Previous studies with Galidesivir have demonstrated a 94% survival rate in treated non-human primates. The results, expected in the second half of 2026, will provide critical data towards a pivotal confirmatory efficacy study, enhancing Island's engagement with US biodefense efforts.
Key Points
  • Island Pharmaceuticals Limited updated its CRADA with USAMRIID.
  • The expanded CRADA supports a Galidesivir dose optimisation study for Marburg Virus Disease.
  • USAMRIID is the primary research institute of the US Army for infectious diseases.
  • The study aims to identify the minimally effective Galidesivir dose against the Marburg Angola strain.
  • Dosing will begin 24 or 48 hours after exposure and continue for 14 days.
  • Previous studies showed a 94% survival rate for Galidesivir-treated primates.
  • Results from the study are expected in the second half of calendar year 2026.
  • The study is critical for advancing towards a pivotal confirmatory efficacy study.
  • Island Pharmaceuticals is strengthening its connection with US biodefense stakeholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.